Results 11 to 20 of about 12,023 (229)
Dopamine and prolactin in migraine: Mechanisms and potential therapeutic targets. [PDF]
J NeuroendocrinolProlactin and dopamine modulate migraine‐relevant trigeminal pathways. Hyperprolactinemia is associated with migraine‐like headache, and preclinical studies show that prolactin enhances trigeminal excitability, particularly in females. Dopamine inhibits prolactin release and may also directly suppress trigeminovascular activity via D2 receptors in the ...
Hjelholt AJ +3 more
europepmc +2 more sources
BMC Endocrine Disorders, 2020 Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr +6 more
doaj +1 more source
Journal of Electrochemical Science and Engineering, 2021 The electrochemical sensor was fabricated for the simultaneous determination of levodopa and cabergoline using carbon paste electrode (CPE) modified with graphene quantum dots (GQD), 2-chlorobenzoyl ferrocene (2CBF) and ionic liquid (IL).
Peyman Mohammadzadeh Jahani
doaj +1 more source
A Combination of Exercise and Therapy with Cabergoline Attenuate Disturbances of Pituitary-Gonadal Hormones in Hyperprolactinemic Male Patients [PDF]
Montenegrin Journal of Sports Science and Medicine, 2020 This study aimed to investigate whether cabergoline therapy alone for six months or in combination with a light exercise programme for an additional three months can attenuate hyperprolactinemia in 13 male patients (range: 22 to 45 yrs.) through ...
Mohammad Fayiz AbuMoh'd +3 more
doaj +1 more source
Diabetes mellitus remission in a cat with hyperadrenocorticism after cabergoline treatment
Journal of Feline Medicine and Surgery Open Reports, 2021 Case summary A 7-year-old spayed female domestic shorthair cat weighing 5 kg was referred with polyuria, polydipsia, lethargy, abdominal distension and dermatologic abnormalities.
Diego D Miceli +4 more
doaj +1 more source
Journal of Pharmacological Sciences, 2006 .: Cabergoline is used in the treatment of Parkinson’s disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice.
Akiko Nakatsuka +7 more
doaj +1 more source
Hyperprolactinemia induced by hCG leads to metabolic disturbances in female mice [PDF]
, 2016 The metabolic syndrome is a growing epidemic; it increases the risk for diabetes, cardiovascular disease, fatty liver, and several cancers. Several reports have indicated a link between hormonal imbalances and insulin resistance or obesity.
Bonaventura, Maria Marta +7 more
core +1 more source
BMC Pharmacology and Toxicology, 2021 Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby +6 more
doaj +1 more source
A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology [PDF]
, 2016 Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and ...
Ansorge, Olaf +6 more
core +3 more sources
Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas [PDF]
Endocrinology and Metabolism, 2014 BackgroundCabergoline is typically effective for treating prolactinomas; however, some patients display cabergoline resistance, and the early characteristics of these patients remain unclear.
Youngki Lee +5 more
doaj +1 more source